Joint Oncologie and Merck Phase II Trial Announced for Gastric and Gastroesophageal Cancers

September 9, 2019

New Report Highlights Risks of U.S. Drug Reimportation

Oncologie and Merck will launch a phase II trial to investigate Merck’s Keytruda (pembrolizumab) and Oncologie’s bavituximab, an antibody that blocks the activity of phosphatidylserine (PS) in advanced gastric or gastroesophageal cancer. International trials like this one — enrolling patients in the United States, the UK, Korea, and Taiwan — are a particular specialty at Yourway.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group Asia Pacific Conference

March 10-12, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

Schedule a Meeting

Media

Articles

Why Integration Matters in Clinical Supply Chains

Open chat

Hello! How can I help you?